Returning guests Sanam Loghavi, MD, hematopathologist and molecular pathologist, University of Texas MD Anderson Center, and Aaron Goodman, MD, hematologist, University of California San Diego, break down the latest classification system updates in leukemia. They begin by explaining what triggers a new classification and why it is needed, how soon clinicians should adopt it, and the relationship as well as differences between the ICC and WHO classification systems. Then, the experts go into the details of the changes that have been made to AML and MDS diagnoses and how these are likely to impact clinical trials, among other important points.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
